Payment overview · 2025
General Payments
$525.19
23 reported records · 14 companies
Healthcare provider profile · identity verified
John Terry Fowler, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BEAUMONT, TX · NPI 1528075348
Verified facts
What the public records show
CMS Open Payments records show John Terry Fowler, M.D. received $525.19 in general payments during 2025 across 23 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $107.29 | 20.4% | 5 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $99.66 | 19.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $45.96 | 8.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.70 | 7.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $40.51 | 7.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.97 | 6.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.40 | 4.5% | 1 | 2025 |
| Krystal Biotech Inc | Unresolved — no canonical attribution shown | $22.65 | 4.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.28 | 4.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.76 | 3.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$19.50 | 3.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.86 | 3.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.49 | 3.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.16 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $525.19 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $128.57 | 6 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $99.66 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $45.96 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $40.51 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $33.97 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $25.87 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $25.87 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $25.87 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| VYJUVEK Normalized: vyjuvek |
Drug | Krystal Biotech Inc | $22.65 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 101 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 101 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
50 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
54 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
95 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
101 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
101 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
145 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 689 | 209 |
| Amlodipine Besylate | Amlodipine Besylate | 681 | 196 |
| Pantoprazole Sodium | Pantoprazole Sodium | 529 | 168 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 477 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 463 | 132 |
| Gabapentin | Gabapentin | 440 | 137 |
| Levothyroxine Sodium | Levothyroxine Sodium | 440 | 133 |
| Hydrochlorothiazide | Hydrochlorothiazide | 335 | 99 |
| Allopurinol | Allopurinol | 324 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 314 | 95 |
| Alprazolam | Alprazolam | 310 | 69 |
| Losartan Potassium | Losartan Potassium | 299 | 91 |
| Lisinopril | Lisinopril | 284 | 91 |
| Omeprazole | Omeprazole | 272 | 80 |
| Zolpidem Tartrate | Zolpidem Tartrate | 259 | 63 |
| Furosemide | Furosemide | 225 | 76 |
| Metformin Hcl | Metformin Hcl | 213 | 67 |
| Montelukast Sodium | Montelukast Sodium | 211 | 66 |
| Clopidogrel | Clopidogrel Bisulfate | 204 | 63 |
| Simvastatin | Simvastatin | 203 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 202 | 63 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 194 | 53 |
| Potassium Chloride | Potassium Chloride | 193 | 54 |
| Metformin Hcl Er | Metformin Hcl | 183 | 46 |
| Carvedilol | Carvedilol | 180 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 171 | 40 |
| Meloxicam | Meloxicam | 169 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 169 | 45 |
| Famotidine | Famotidine | 156 | 50 |
| Sertraline Hcl | Sertraline Hcl | 153 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 150 | 46 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 146 | 42 |
| Eliquis | Apixaban | 145 | 29 |
| Clonazepam | Clonazepam | 137 | 31 |
| Glimepiride | Glimepiride | 133 | 36 |
| Trazodone Hcl | Trazodone Hcl | 132 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 34 |
| Tramadol Hcl | Tramadol Hcl | 112 | 37 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 103 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 29 |
| Mounjaro | Tirzepatide | 101 | 22 |
| Ozempic | Semaglutide | 101 | 25 |
| Bupropion Xl | Bupropion Hcl | 97 | 21 |
| Atenolol | Atenolol | 96 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 96 | 37 |
| Farxiga | Dapagliflozin Propanediol | 95 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 95 | 52 |
| Nifedipine Er | Nifedipine | 92 | 24 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 91 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 87 | 31 |
| Celecoxib | Celecoxib | 82 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 82 | 23 |
| Eszopiclone | Eszopiclone | 80 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 80 | 25 |
| Methocarbamol | Methocarbamol | 80 | 25 |
| Xarelto | Rivaroxaban | 79 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 78 | 20 |
| Temazepam | Temazepam | 74 | 14 |
| Januvia | Sitagliptin Phosphate | 73 | 16 |
| Lorazepam | Lorazepam | 73 | 14 |
| Mirtazapine | Mirtazapine | 72 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 71 | 23 |
| Telmisartan | Telmisartan | 71 | 20 |
| Spironolactone | Spironolactone | 70 | 25 |
| Ezetimibe | Ezetimibe | 66 | 21 |
| Valsartan | Valsartan | 64 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 63 | 15 |
| Azelastine Hcl | Azelastine Hcl | 62 | 27 |
| Jardiance | Empagliflozin | 59 | suppressed |
| Chlorthalidone | Chlorthalidone | 57 | 15 |
| Alendronate Sodium | Alendronate Sodium | 56 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 56 | 12 |
| Donepezil Hcl | Donepezil Hcl | 56 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | 15 |
| Mupirocin | Mupirocin | 54 | 27 |
| Synthroid | Levothyroxine Sodium | 54 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 53 | 22 |
| Ramipril | Ramipril | 53 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 53 | 21 |
| Clonidine Hcl | Clonidine Hcl | 52 | 20 |
| Estradiol | Estradiol | 52 | 15 |
| Irbesartan | Irbesartan | 51 | 15 |
| Memantine Hcl | Memantine Hcl | 51 | 11 |
| Linzess | Linaclotide | 50 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 50 | 18 |
| Ondansetron Odt | Ondansetron | 49 | 15 |
| Cefdinir | Cefdinir | 48 | 46 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 11 |
| Pregabalin | Pregabalin | 48 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 13 |
| Myrbetriq | Mirabegron | 47 | 11 |
| Buspirone Hcl | Buspirone Hcl | 44 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 43 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 34 |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 39 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 38 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 37 | 11 |
| Benazepril Hcl | Benazepril Hcl | 37 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 37 | suppressed |
| Prednisone | Prednisone | 37 | 13 |
| Trulicity | Dulaglutide | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Finasteride | Finasteride | 35 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 35 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Fluconazole | Fluconazole | 33 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | 12 |
| Risedronate Sodium | Risedronate Sodium | 33 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Ibuprofen | Ibuprofen | 30 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 27 | suppressed |
| Lidocaine | Lidocaine | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Cilostazol | Cilostazol | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 25 | suppressed |
| Nystatin | Nystatin | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Carisoprodol | Carisoprodol | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 13 |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Nabumetone | Nabumetone | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 15 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Livalo | Pitavastatin Calcium | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 16 | suppressed |
| Nadolol | Nadolol | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Mirabegron Er | Mirabegron | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Clobetasol Propionate | Clobetasol Propionate | 14 | 11 |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 13 | suppressed |
| Nexletol | Bempedoic Acid | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Zafirlukast | Zafirlukast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $525.19 · 23 records | Otsuka America Pharmaceutical, Inc. | ABRYSVO, AIRSUPRA, COMIRNATY, GVOKE HYPOPEN, INCEPTIV, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Omnipod, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VYJUVEK, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error